fam-trastuzumab deruxtecan-nxki,trastuzumab deruxtecan,ruxolitinib
novartis,daiichi sankyo,incyte,astrazeneca
['trastuzumab deruxtecan', 'rux,(-crux),(-trux)', 'fam-trastuzumab deruxtecan-nxki', 'solid tumor', 'pantumor', 'fam-trastuzumab', 'destiny,pantumor02']
across a wide range of her2 expressing solid tumors, treatment with fam-trastuzumab deruxtecan-nxki demonstrated clinically meaningful activity, according to the phase 2 destiny-pantumor02 trial. #asco2023 | 
Oncology news and insights from leading researchers and cancer centers.